Endocrine and Metabolic Clinical Trials
Advancing science for global impact
Diseases of the endocrine and metabolic systems — diabetes, dyslipidemia, steatotic liver disease, kidney disease, obesity and other disorders — are urgent public health issues around the world that demand innovative and accelerated solutions.
The opportunity to make a meaningful difference in the lives of patients struggling with these conditions is what motivates us every day.
Since 2020:
350+
Studies
10K+
Sites
59K+
Patients
In a recent 5-year period, Syneos Health helped to develop or commercialize a significant percentage of novel endocrine/metabolic drugs (2021-2025):
90%
of those approved by the FDA
92%
of those approved by the EMA
Ready to see what our Endocrine and Metabolic team can do for you?
Partnering with you to meet complex challenges
More than a CRO, we work with innovative companies at the forefront of endocrinology clinical research. This includes small to midsize biotech companies who rely on us to meet them where they are on the drug development continuum and become true partners in meeting complex challenges.
We’ve worked across the entire spectrum of endocrine and metabolic indications including:
- Diabetes and its complications
- Dyslipidemia
- Growth hormone disorders
- Steatotic liver disease
- Kidney disease
- Metabolic syndrome
- Obesity
- Rare metabolic disease
Driven by rising rates of obesity and diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) – formerly known as nonalcoholic fatty liver disease (NAFLD) – and metabolic dysfunction-associated steatohepatitis (MASH) – formerly known as nonalcoholic steatohepatitis (NASH) – have replaced hepatitis C virus infection as the most common cause of chronic liver disease worldwide. Our team's extensive experience in metabolic disease clinical trials and MASH clinical trials enables us to become true partners in meeting complex challenges across the full spectrum of metabolic and endocrine conditions.
Your global strategy, and an expert team in every market
We leverage our deep therapeutic expertise, insights and capabilities across our global team to connect you with highly trained personnel who are not only therapeutically focused but also understand how to match regional regulatory requirements to your global registration strategy.
Enduring site relationships for endocrine and metabolic studies
Fierce competition for investigators, sites and patients is a given in this field. We tap our vast global database of experienced endocrine metabolic specialists and investigators with whom we have long-term relationships to match each site's specific capabilities to your study requirements.
Finding eligible patients for metabolic disease clinical trials is further complicated by the need to target specific subgroups to meet protocol-specific inclusion/exclusion criteria. In addition to working with sites to develop and implement effective recruitment strategies for endocrine and metabolic disorders, we maintain large databases of specialty patient populations around the world.
Improving the patient experience
The contributions patients can make to the clinical research enterprise are invaluable. We learn from them and map their journey to inform study protocols, and help reduce the burden of trial participation by using home health, telemedicine and digital technology platforms to facilitate decentralized solutions.
Our patient-centric approach to metabolic and endocrine research prioritizes convenience and accessibility while maintaining the highest standards of clinical data integrity. We increase site and patient retention and accelerate your speed to market through innovative trial design and operational excellence.
Syneos Health combines therapeutic alignment, deep insights, leading technologies, innovative trial design experience and operational excellence to bring clinical trials closer to the patient, increase site and patient retention and accelerate your speed to market.
Clinical studies in endocrine and metabolic diseases face unique complexities. Conditions such as diabetes, obesity and rare hormonal disorders are often chronic, heterogeneous and genetic, with comorbidities and long disease timelines. Trials must account for variable patient populations, evolving standards of care and the need for long-term efficacy and safety data. Recruiting and retaining appropriate patients, managing adherence and selecting meaningful endpoints are persistent challenges.
At Syneos Health, we are advancing innovative clinical trial designs focused on flexibility, precision and patient experience. Adaptive and seamless trial designs enable earlier decision-making and more efficient development pathways. Decentralized and hybrid models, including home health, telemedicine and digital technologies and wearables, help reduce patient burden and improve recruitment, retention and titration. Data-driven feasibility, targeted recruitment of specific subpopulations, and the use of real-world data and digital endpoints are also advancing trial efficiency, improving data quality and better reflecting real-world disease management.
Related Content
Looking for exclusive insight?
